« Back
Home /
Cabozantinib (S-malate)

Cabozantinib (S-malate)

Item no.	HY-12044-100mg
Manufacturer	MedChem Express
CASRN	1140909-48-3
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 500 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	99.90
Citations	[1]You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71(14), 4758-4768.\|[2]Torres KE, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res, 2011, 17(12), 3943-3955.\|[3]Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10(12), 2298-2308. Harvard Medical School LINCS LIBRARY\|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.\|Adv Healthc Mater. 2023 Aug 21;e2302046.\|Am J Reprod Immunol. 2021 Mar;85(3):e13352.\|Antioxidants (Basel). 2021, 10(9), 1336.\|Biochem Biophys Rep. 2020 Jan 17;21:100726.\|Biochem Biophys Res Commun. 2024 Nov 19:734:150781.\|Biomaterials. 16 September 2022.\|Biomed Chromatogr. 2020 Aug;34(8):e4862.\|Biomed Chromatogr. 2023 May 15;e5685.\|Biomed Chromatogr. 2024 Jan 30:e5833.\|Biomedicines. 2020 Nov 28;8(12):547.\|bioRxiv. 2023 Apr 14.\|bioRxiv. 2024 November 03.\|BMC Biol. 2024 Oct 1;22(1):222.\|Br J Cancer. 2024 Jun 20.\|Cancer Discov. 2021 Jan;11(1):126-141.\|Cancer Lett. 2019 Apr 10;447:105-114.\|Cancers (Basel). 2024 Jan 8, 16(2), 269.\|Drug Des Devel Ther. 2018 Apr 30;12:1009-1017.\|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Front Oncol. 2022 Jul 7;12:915319.\|Fundam Clin Pharmacol. 2021 Feb 1.\|Int J Mol Sci. 2022 Sep 14;23(18):10677.\|Invest Ophthalmol Vis Sci. 2022 Dec 1;63(13):14.\|J Cell Biochem. 2020 Mar;121(3):2343-2353.\|J Med Chem. 2016 Jan 14;59(1):358-73.\|J Neurosci. 2020 Dec 9;40(50):9602-9616.\|J Pharm Anal. 2021 Jun 19.\|J Transl Med. 2023 Jan 9;21(1):9.\|Mediat Inflamm. 2020 Oct 24;2020:1649453.\|Mol Cancer Res. 2019 Feb;17(2):499-507. \|Mol Cancer Ther. 2017 Nov;16(11):2387-2398.\|Patent. US20170349880A1.\|Patent. US20220332731A1.\|PLoS One. 2017 Sep 25;12(9):e0185321. \|PLoS One. 2024 Nov 1;19(11):e0308647.\|React Kinet Mech Cat. 07 January 2022.\|Saudi Pharm J. 2023 Aug 24, 101756.\|Sci Rep. 2019 Nov 12;9(1):16600.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Spectrochim Acta A Mol Biomol Spectrosc. 2016 Apr 15;159:199-208.
Smiles	O=C([C@H](CC(O)=O)O)O.O=C(NC1=CC=C(C=C1)OC2=CC=NC3=CC(OC)=C(C=C23)OC)C4(CC4)C(NC5=CC=C(C=C5)F)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	XL184 (S-malate),BMS-907351 (S-malate)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; VEGFR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	635.59
Product Description	Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)\|H2O: < 0.1 mg/mL
Manufacturer - Pathway	Apoptosis; Protein Tyrosine Kinase/RTK
Isoform	VEGFR2/KDR/Flk-1
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12044-100mg-safety-datasheet.pdf